A structure-guided strategy to design Golgi apparatus-targeted type-I/II aggregation-induced emission photosensitizers for efficient photodynamic therapy
Source abstract
Abstract
The Golgi apparatus (GA) is a vital target for anticancer therapy due to its sensitivity against reactive oxygen species (ROS)-induced oxidative stress that could lead to cell death. In this study, we designed a series of aggregation-induced emission (AIE)-based photosensitizers (TPAPyTZ, TPAPyTC, TPAPyTM, and TPAPyTI) carrying different ROS with selective GA-targeted ability. The in vitro study showed that TPAPyTZ and TPAPyTC displayed strong AIE characteristics, robust type-I/II ROS production capabilities, specific GA-targeted, high photostability, and high imaging quality. The cell-uptake of TPAPyTZ was found primarily through an energy-dependent caveolae/raft-mediated endocytosis pathway. Remarkably, TPAPyTZ induced GA-oxidative stress, leading to GA fragmentation, downregulation of GM130 expression, and activation of mitochondria caspase-related apoptosis during photodynamic therapy (PDT). In vivo experiments revealed that TPAPyTZ significantly inhibited tumor proliferation under lower-intensity white light irradiation with minimal side effects. Overall, our work presents a promising strategy for designing AIEgens for fluorescence imaging-guided PDT. Additionally, it enriched the collection of GA-targeted leads for the development of cancer theranostics capable of visualizing dynamic changes in the GA during cancer cell apoptosis, which could potentially enable early diagnosis applications in the future. STATEMENT OF SIGNIFICANCE: AIE luminogens (AIEgens) are potent phototheranostic agents that can exhibit strong fluorescence emission and enhance ROS production in the aggregate states. In this study, through the precise design of photosensitizers with four different electron-acceptors, we constructed a series of potent AIEgens (TPAPyTZ, TPAPyTC, TPAPyTM, and TPAPyTI) with strong fluorescence intensity and ROS generation capacity. Among them, TPAPyTZ with an extended π-conjugation displayed the strongest ROS generation ability and anti-tumor activity, resulting in an 88 % reduction in tumor weight. Our studies revealed that the enhanced activity of TPAPyTZ may be due to its unique Golgi apparatus (GA)-targeted ability, which causes GA oxidative stress followed by effective cancer cell apoptosis. This unique GA-targeted feature of TPAPyTZ remains rare in the reported AIEgens, which mainly target organelles such as lysosome, mitochondria, and cell membrane. The successful design of a GA-targeted and potent AIEgen could enrich the collection of GA-targeted luminogens, providing a lead theranostic for the further development of fluorescence imaging-guided PDT, and serving as a tool to explore the potential mechanism and discover new GA-specific drug targets.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Luminescence and Fluorescent Materials · Molecular Sensors and Ion Detection
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (63)
Show source-provided references
1. Nanoparticles in photodynamic therapy10.1021/cr5004198 ↗
2. Engineering of electrochromic materials as activatable probes for molecular imaging and photodynamic therapy10.1021/jacs.8b10176 ↗
3. A highly efficient and photostable photosensitizer with near-infrared aggregation-induced emission for image-guided photodynamic anticancer therapy10.1002/adma.201700548 ↗
4. Amphiphilic porphyrin-based supramolecular self-assembly for photochemotherapy: from molecular design to application10.1016/j.nantod.2022.101732 ↗
5. Recent progress in photosensitizers for overcoming the challenges of photodynamic therapy: from molecular design to application10.1039/D0CS00173B ↗
6. Instant ultrasound-evoked precise nanobubble explosion and deep photodynamic therapy for tumors guided by molecular imaging10.1021/acsami.1c05517 ↗
7. Photoacoustic molecular imaging-escorted adipose photodynamic–browning synergy for fighting obesity with virus-like complexes10.1038/s41565-020-00844-6 ↗
8. Tumor microenvironment activated photoacoustic-fluorescence bimodal nanoprobe for precise chemo-immunotherapy and immune response tracing of glioblastoma10.1021/acsnano.3c03378 ↗
9. Aggregation-induced emission-active micelles: synthesis, characterization, and applications10.1039/D2CS01021F ↗
10. AIE luminogens for bioimaging and theranostics: from organelles to animals10.1016/j.chempr.2017.05.010 ↗
11. One-step formulation of targeted aggregation-induced emission dots for image-guided photodynamic therapy of cholangiocarcinoma10.1021/acsnano.7b00312 ↗
12. Aggregation-induced emission of 1-methyl-1,2,3,4,5-pentaphenylsilole10.1039/b105159h ↗
13. AIEgens for biological process monitoring and disease theranostics10.1016/j.biomaterials.2017.09.004 ↗
14. Development of organic semiconducting materials for deep-tissue optical imaging, phototherapy and photoactivation10.1039/C8CS00001H ↗
15. Molecular packing: another key point for the performance of organic and polymeric optoelectronic materials10.1021/acs.accounts.0c00060 ↗
16. Aggregation-induced emission luminogens for activity-based sensing10.1021/acs.accounts.9b00305 ↗
17. State-of-the-art self-luminescence: a win–win situation10.1039/D2CS00228K ↗
18. Aggregation effect on multiperformance improvement in aryl-armed phenazine-based emitters10.1021/jacs.2c09210 ↗
19. Aggregation-induced emission materials: a platform for diverse energy transformation and applications10.1039/D2TA09630G ↗
20. Aggregation-induced emission: together we shine, united we soar10.1021/acs.chemrev.5b00263 ↗
21. Aggregation-induced emission photosensitizers: from molecular design to photodynamic therapy10.1021/acs.jmedchem.9b02014 ↗
22. Three birds with one stone: acceptor engineering of hemicyanine dye with NIR-II emission for synergistic photodynamic and photothermal anticancer therapy10.1002/smll.202204851 ↗
23. Photoactivatable dihydroalkaloids for cancer cell imaging and chemotherapy with high spatiotemporal resolution10.1039/D0MH00931H ↗
24. A mitochondrion-specific photoactivatable fluorescence turn-on AIE-based bioprobe for localization super-resolution microscope10.1002/adma.201505906 ↗
25. Multiple yet controllable photoswitching in a single AIEgen system10.1021/jacs.7b13364 ↗
26. Solid-state photoinduced luminescence switch for advanced anticounterfeiting and super-resolution imaging applications10.1021/jacs.7b07738 ↗
27. Photochemical C−H hydroxyalkylation of quinolines and isoquinolines10.1002/anie.201910641 ↗
28. Tuning organelle specificity and photodynamic therapy efficiency by molecular function design10.1021/acsnano.9b04430 ↗
29. Calixarene-based supramolecular AIE dots with highly inhibited nonradiative decay and intersystem crossing for ultrasensitive fluorescence image-guided cancer surgery10.1002/anie.201916430 ↗
30. An all-round athlete on the track of phototheranostics: subtly regulating the balance between radiative and nonradiative decays for multimodal imaging-guided synergistic therapy10.1002/adma.202003210 ↗
31. Making the best use of excited-state energy: multimodality theranostic systems based on second near-infrared (NIR-II) aggregation-induced emission luminogens (AIEgens)10.1021/acsmaterialslett.0c00263 ↗
32. Zwitterionic AIEgens: rational molecular design for NIR-II fluorescence imaging-guided synergistic phototherapy10.1002/adfm.202007026 ↗
33. GSH and H2O2 co-activatable mitochondria-targeted photodynamic therapy under normoxia and hypoxia10.1002/anie.202003895 ↗
34. Mitochondria-targeted small-molecule fluorophores for dual modal cancer phototherapy10.1002/adfm.201600159 ↗
35. Highly efficient photodynamic therapy with mitochondria-targeting aggregation-induced emission photosensitizer for retinoblastoma
36. ER-targeting cyanine dye as an NIR photoinducer to efficiently trigger photoimmunogenic cancer cell death10.1021/jacs.1c11886 ↗
37. A light-up endoplasmic reticulum probe based on a rational design of red-emissive fluorogens with aggregation-induced emission10.1039/C7CC05205G ↗
38. Synthesis of fluorophores that target small molecules to the endoplasmic reticulum of living mammalian cells10.1002/anie.201504156 ↗
39. Red AIE luminogens with tunable organelle specific anchoring for live cell dynamic super resolution imaging10.1002/adfm.202009329 ↗
40. Highly charged ruthenium(Ⅱ) polypyridyl complexes as lysosome-localized photosensitizers for two-photon photodynamic therapy10.1002/ange.201507800 ↗
41. Photooxidation-driven purely organic room-temperature phosphorescent lysosome-targeted imaging10.1021/jacs.1c06741 ↗
42. A NIR-I light-responsive superoxide radical generator with cancer cell membrane targeting ability for enhanced imaging-guided photodynamic therapy10.1039/D0SC03093G ↗
43. Amphiphilic tetraphenylethene-based pyridinium salt for selective cell-membrane imaging and room-light-induced special reactive oxygen species generation10.1021/acsami.9b00643 ↗
44. Engineered platelet microparticle-membrane camouflaged nanoparticles for targeting the Golgi apparatus of synovial fibroblasts to attenuate rheumatoid arthritis10.1021/acsnano.2c06584 ↗
45. Golgi apparatus-targeted chondroitin-modified nanomicelles suppress hepatic stellate cell activation for the management of liver fibrosis10.1021/acsnano.8b06924 ↗
46. Supramolecular insights into domino effects of Ag@ZnO-induced oxidative stress in melanoma cancer cells10.1021/acsami.9b13420 ↗
47. Enzyme-responsive peptide thioesters for targeting Golgi apparatus10.1021/jacs.2c02238 ↗
48. The flashlights on a distinct role of protein kinase C δ: phosphorylation of regulatory and catalytic domain upon oxidative stress in glioma cells10.1016/j.cellsig.2017.02.020 ↗
49. Regulating the Golgi apparatus by co-delivery of a COX-2 inhibitor and brefeldin A for suppression of tumor metastasis10.1039/C8BM00381E ↗
50. Ror2 signaling regulates Golgi structure and transport through IFT20 for tumor invasiveness10.1038/s41598-016-0028-x ↗
51. High performance photosensitizers with aggregation-induced emission for image-guided photodynamic anticancer therapy10.1039/C7MH00469A ↗
52. All-in-one theranostic platforms: deep-red AIE nanocrystals to target dual-organelles for efficient photodynamic therapy10.1021/acsnano.2c04465 ↗
53. Development of sulfonamide-functionalized charge-reversal AIE photosensitizers for precise photodynamic therapy in the acidic tumor microenvironment10.1002/adfm.202300746 ↗
54. Tailoring the amphiphilic structure of zwitterionic AIE photosensitizers to boost antitumor immunity10.1002/adma.202303186 ↗
55. Golgi apparatus-targeted aggregation-induced emission luminogens for effective cancer photodynamic therapy10.1038/s41467-022-29872-7 ↗
56. Distinct caveolae-mediated endocytic pathways target the Golgi apparatus and the endoplasmic reticulum10.1242/jcs.00327 ↗
57. Ganglioside GM1 levels are a determinant of the extent of caveolae/raft-dependent endocytosis of cholera toxin to the Golgi apparatus10.1242/jcs.01009 ↗
58. Enzymatic assemblies of thiophosphopeptides instantly target Golgi apparatus and selectively kill cancer cells10.1002/anie.202102601 ↗
59. Golgins and GRASPs: holding the Golgi together10.1016/j.semcdb.2009.03.011 ↗
60. Finding the Golgi: golgin coiled-coil proteins show the way10.1016/j.tcb.2016.02.005 ↗
61. The vesicle docking protein p115 binds GM130, a cis-Golgi matrix protein, in a mitotically regulated manner10.1016/S0092-8674(00)80225-1 ↗
62. Golgi organization is regulated by proteasomal degradation10.1038/s41467-019-14038-9 ↗
63. Characterization of a cis-Golgi matrix protein, GM13010.1083/jcb.131.6.1715 ↗